Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

ACC pipeline

What is next, and who is running it?

The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.

A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.

Include Phase 1
ClassNone selected

21 of 23 programs on this timeline

202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today

B7-H4-directed ADC 2

EMBLEM-1 first patients dosed, Oct 19, 2026
No dated milestone in 2025 to 2030

CXCR1/2 inhibitor 1

No dated milestone in 2025 to 2030

EGFR x MET bispecific antibody 1

No dated milestone in 2025 to 2030

gamma secretase inhibitor 1

No dated milestone in 2025 to 2030

HDAC inhibitor 1

HG146Phase 2
No dated milestone in 2025 to 2030

MDM2 inhibitor 1

No dated milestone in 2025 to 2030

multi-kinase TKI 1

No dated milestone in 2025 to 2030

multi-kinase TKI with chemotherapy 1

No dated milestone in 2025 to 2030

MYB mRNA degrader 1

REM-422Phase 1/2
No dated milestone in 2025 to 2030

Nectin-4-directed ADC 1

No dated milestone in 2025 to 2030

pan-NOTCH transcription inhibitor 1

CB-103Phase 1/2
No dated milestone in 2025 to 2030

PD-1 x VEGF bispecific 1

No dated milestone in 2025 to 2030

PSMA radioligand 1

No dated milestone in 2025 to 2030

TrkA inhibitor 1

VMD-928Phase 1/2
No dated milestone in 2025 to 2030

TROP2-directed ADC 1

No dated milestone in 2025 to 2030

VEGFR multi-kinase TKI 1

No dated milestone in 2025 to 2030

VEGFR TKI 1

No dated milestone in 2025 to 2030

VEGFR/MET/TAM TKI 1

No dated milestone in 2025 to 2030

VEGFR2 TKI 2

RivoceranibTrials stopped
No dated milestone in 2025 to 2030
ApatinibPhase 2
No dated milestone in 2025 to 2030